Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11254670 1,8-naphthyridinone compounds and uses thereof

Patent 11254670 was granted and assigned to Nuvation Bio on February, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Nuvation Bio
Nuvation Bio
Date Filed
January 17, 2020
Date of Patent
February 22, 2022
Patent Applicant
Nuvation Bio
Nuvation Bio
Patent Application Number
16746769
Patent Citations
‌
US Patent 10336697 Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
‌
US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors
‌
US Patent 10363257 Bicyclic bromodomain inhibitors
‌
US Patent 10370356 Pyridinone dicarboxamide for use as bromodomain inhibitors
‌
US Patent 10370374 Heterocyclic compounds and uses thereof
‌
US Patent 10377769 Benzopiperazine compositions as BET bromodomain inhibitors
‌
US Patent 10391175 BET bromodomain inhibitors and therapeutic methods using the same
‌
US Patent 10399962 Azolopyrimidine for the treatment of cancer-related disorders
‌
US Patent 10472347 Aminopyrazine compounds with A2A antagonist properties
‌
US Patent 11028058 Heterocyclic compounds as adenosine antagonists
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11254670
Patent Primary Examiner
‌
Niloofar Rahmani

Find more entities like US Patent 11254670 1,8-naphthyridinone compounds and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.